Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Vanosdol

Surgery Spearfish, SD Medical Doctor

NPI 1710203401 CMS profile 1309495

1445 North Ave, Spearfish, SD 57783

Open in the dashboard

General payments

$13,529

79 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Vanosdol of Spearfish, SD is reported in the CMS Open Payments database as having received $13,529 across 79 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17 1
2024 General $149 3
2023 General $3,643 22
2022 General $1,714 13
2021 General $342 7
2020 General $367 9
2019 General $7,296 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Vanosdol
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Andrew Vanosdol were reported at $17. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Andrew Vanosdol Surgery median Middle half National median
2019 $7,296 $253 $82–$1,521 $163
2020 $367 $131 $40–$706 $114
2021 $342 $168 $50–$904 $132
2022 $1,714 $224 $76–$1,218 $149
2023 $3,643 $253 $82–$1,255 $160
2024 $149 $279 $90–$1,381 $164
2025 $17 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ethicon US, LLC $5,353 19 payments
  2. Intuitive Surgical, Inc. $3,603 19 payments
  3. Medical Device Business Services, Inc. $2,201 9 payments
  4. Stryker Corporation $1,533 11 payments
  5. Endogastric Solutions, Inc $156 5 payments
  6. Steris Corporation $108 1 payment
  7. Boston Scientific Corporation $73 1 payment
  8. Davol Inc. $73 1 payment
  9. Medtronic Vascular, Inc. $53 1 payment
  10. Sioux Surgical Inc $52 1 payment
  11. Other $324 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $5,779 17 payments
  2. Consulting Fee $4,680 1 payment
  3. Food and Beverage $3,054 60 payments
  4. Gift $16 1 payment
Products named General payments · program years 2019–2025
  1. LINX Reflux Management System Endo-Mechanical $7,206 20 payments
  2. Da Vinci Surgical System $3,603 19 payments
  3. S-SERIES $1,298 8 payments
  4. LINX Reflux Management System Endo-Mechanical $167 3 payments
  5. EsophyX $156 5 payments
  6. SDC3 $154 1 payment
  7. TruFreeze $108 1 payment
  8. SPY TECHNOLOGY $81 2 payments
  9. Phasix Mesh $73 1 payment
  10. ClosureFast $53 1 payment
  11. Other $594 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

224

Median for General Surgery: 59

Drug cost

$2,876

Median for General Surgery: $393

Branded share of claims

16.5%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Omeprazole Generic 104 $1,325
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 25 $413
Pantoprazole Sodium Generic 35 $321
Fluconazole Generic 13 $285
Sucralfate Generic 11 $256
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 12 $211
Prednisone Generic 11 $34
Gabapentin Generic 13 $31

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$61,697

Medicare's payments for the services billed

Medicare patients

192

Average age 70

Services billed

417

131 women, 61 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 44%
Depression 22%
Osteoporosis 22%
Diabetes 19%
Ischemic heart disease 16%
COPD 14%
Atrial fibrillation 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

79 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in South Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record